Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas

NCT05010005 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT05010005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05010005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
August 12, 2021
Completion date
August 31, 2027
Enrollment
70 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

nk-cell lymphomas, t-cell large granular lymphocyte leukemia, t-cell lymphomas, t-cell prolymphocytic leukemia